Market Place
Sourcing Support
Silo Pharma Announces Positive SPC-15 Results for Stress Disorders
18 Nov 2024 //
GLOBENEWSWIRE
Silo Pharma Reports Positive SP-26 Ketamine Implant Results
31 Oct 2024 //
GLOBENEWSWIRE
Silo Pharma Completes FDA Pre-IND Meeting For SPC-15
10 Sep 2024 //
GLOBENEWSWIRE
Silo Pharma Partners With Global CRO For CNS Homing Peptide
07 Aug 2024 //
GLOBENEWSWIRE
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
26 Jul 2024 //
GLOBENEWSWIRE
Silo Pharma Closes $2.1M At-Market Registered Direct Offering
22 Jul 2024 //
GLOBENEWSWIRE
Silo Pharma Announces $2.1M At-Market Registered Direct Offering
19 Jul 2024 //
GLOBENEWSWIRE
Silo Pharma And Resyca Partner On Intranasal PTSD Drug Development
18 Jul 2024 //
GLOBENEWSWIRE
Silo Pharma Secures Exclusive Global License for Alzheimer`s Therapeutic
16 Jul 2024 //
GLOBENEWSWIRE
Silo Pharma Enters Exclusive Global License Agreement to Further Develop SPC-14
16 Jul 2024 //
CONTRACT PHARMA
Silo’s Alzheimer`s ketamine med reduces dementia signs in mice
25 Jan 2024 //
FIERCE BIOTECH
Silo Pharma Reaches Nasal Formulation Milestone for SPC-15
08 Aug 2023 //
CONTRACT PHARMA
Psychedelics Company Silo Working On Time-Release & Dosage Ketamine Implant
23 Jun 2023 //
ACCESSWIRE
Silo Inks Agreement to Develop First-in-Class Ketamine Implant Therapeutic
14 Jun 2023 //
CONTRACT PHARMA
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
31 Dec 2022 //
GLOBENEWSWIRE
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
30 Mar 2022 //
GLOBENEWSWIRE
HaluGen Life Sciences, Announces Psychedelics Genetic Test Kit Partnership
17 Jun 2021 //
GLOBENEWSWIRE
Silo Pharma announces important milestone. Investigator led study Psilocybin
13 May 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.